What You Should Know About the Dupixent Lawsuit

The Dupixent lawsuit involves claims that the drug causes, accelerates, or masks Cutaneous T-Cell Lymphoma (CTCL), a rare cancer, and that manufacturers failed to warn about these serious risks.

Dupixent (dupilumab), a medication manufactured by Sanofi and Regeneron Pharmaceuticals, is widely prescribed for inflammatory conditions like moderate-to-severe atopic dermatitis (eczema), asthma, and chronic rhinosinusitis. While many patients benefit from the drug, recent legal claims allege that its immune-system effects may pose significant risks that were not adequately disclosed on the product’s warning label. If you believe you have suffered injuries due to medical malpractice, reach out to our Pikeville medical malpractice attorneys for a free case evaluation today.

Dupixent’s Masking Effect

A central focus of current litigation is the diagnostic masking effect. Cutaneous T-Cell Lymphoma (CTCL), a type of non-Hodgkin lymphoma, often presents as red, scaly patches on the skin that are nearly indistinguishable from the chronic eczema Dupixent is intended to treat. Plaintiffs argue that because Dupixent suppresses specific immune pathways, it may temporarily alleviate surface inflammation while allowing an underlying, undiagnosed malignancy to progress.

In some cases, the drug is alleged to have unmasked or even accelerated the progression of pre-existing T-cell abnormalities. Plaintiffs claim that because CTCL symptoms can resemble eczema, some patients may have continued treatment while an undiagnosed cancer progressed to more advanced stages. Without a requirement for doctors to screen patients for lymphoma before prescribing the drug, some lawsuits allege individuals may have remained on the medication longer than they otherwise would have.

Failure to Warn

Under product liability law, manufacturers have a strict duty to warn healthcare providers and consumers about known or foreseeable risks. The Dupixent lawsuits allege that the manufacturers knew, or should have known through clinical trials and post-market data, about a potential link between the drug and lymphoid malignancies.

As of 2026, scientific literature has bolstered these claims. Recent epidemiological studies have suggested that patients using Dupixent for certain conditions may face a significantly higher risk of developing Cutaneous T-cell lymphoma compared to those not using the drug. By failing to include this risk in the label’s precautions or warnings sections, the companies allegedly deprived patients of the ability to make an informed choice about their treatment.

2026 Litigation Status and the MDL

As of early 2026, Dupixent litigation is in a critical developmental phase. While lawsuits began as individual claims, plaintiffs filed a motion in February 2026 to consolidate federal cases into a Multidistrict Litigation (MDL). This consolidation is designed to streamline discovery and pretrial proceedings because many cases share common questions of fact regarding the drug’s safety profile and manufacturers’ internal knowledge. At this stage, the litigation process is ongoing, and no global settlement has been announced.

Who May Be Eligible to File a Claim

Eligibility for a legal claim typically requires more than just using the drug. Attorneys are currently reviewing cases for individuals who:

• Used Dupixent to treat eczema, asthma, or any other approved indication
• Were subsequently diagnosed with Cutaneous T-Cell Lymphoma (CTCL) or one of its subtypes including but not limited to, Mycosis Fungoides, Sézary Syndrome, or Peripheral T-cell lymphoma

For residents in the Commonwealth, navigating these complex pharmaceutical claims requires a thorough understanding of medical science and state liability laws. A Kentucky unsafe drugs and medical devices attorney from Gary C. Johnson, P.S.C. can evaluate a patient’s medical history and the specific timeline of their diagnosis to determine if a claim is viable. Those harmed by undisclosed medication risks should receive the advocacy necessary to hold global pharmaceutical corporations accountable for patient safety.